ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2025

Dec 19, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2025-12-17

Reporting Person: Anzalone Christopher Richard (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-17	Common Stock	S	46287	$63.55	Disposed	3870670	Direct
2025-12-17	Common Stock	S	35750	$64.51	Disposed	3834920	Direct
2025-12-17	Common Stock	S	982	$65.53	Disposed	3833938	Direct
2025-12-17	Common Stock	S	1981	$66.30	Disposed	3831957	Direct

Footnotes

F1: Shares sold exclusively to cover anticipated taxes on performance awards that vested December 12, 2025. These performance awards were previously reported on form 4.

F2: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.07 to $64.05, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F3: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

F4: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $64.06 to $64.84, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F5: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.48 to $65.54, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F6: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.03 to $66.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.